Table 7 Opinion of the scientific steering committee – cognitive function

• A switch to aripiprazole should be considered in patients in whom cognitive symptoms appear under treatment with an FGA

• If preservation of cognition function is an issue, aripiprazole would be an appropriate choice of SGA

• To preserve cognitive function, the minimum effective dose of aripiprazole should be identified and used

• In the management of an adult with schizophrenia currently treated with aripiprazole but presenting with residual cognitive symptoms, a dose reduction strategy can be considered

• To preserve cognitive function, aripiprazole monotherapy should be preferred to aripiprazole in combination therapy whenever possible

• Psychosocial interventions, such as cognitive remediation, are recommended together with antipsychotic medication to improve cognition

• In patients otherwise well-controlled on their current antipsychotic medication but presenting with persistent cognitive symptoms, combination with aripiprazole could be considered